---
title: "Descartes-08 in Generalized myasthenia gravis: Heterogeneity of treatment effect"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Heterogeneity of treatment effect. Topics: Descartes-08: AChR antibody-positive subgroup, MGC response at month 3, mITT population (phase 2b); Descartes-08: AChR antibody-positive subgroup, MG-ADL change at month 3 and through month 12 (phase 2b); Descartes-08: AChR antibody status as a marker of response (phase 2b); Descartes-08: biologic-naive versus biologic-exposed participants, post hoc analysis, mITT population (phase 2b); 17 further topics. 21 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Descartes-08: AChR antibody-positive subgroup, MGC response at month 3, mITT population (phase 2b)

> “Similar results were observed for the participants comprising the AChR autoantibody-positive population, with significantly more MGC responders in the Descartes-08 group than in the placebo group (63.6% versus 12.5%, P = 0.025815; Extended Data Table 1).”
> “The mean (s.d.) change from baseline in the MGC score at month 3 for those who were AChR autoantibody-positive was −5.0 (5.62) for the Descartes-08 group and 0.1 (4.85) for those treated with placebo.”
> “Minimum improvements in MGC and MG-ADL scores were higher for the Descartes-08 group than the placebo group at month 3 (Fig. 3), with 81.8% versus 37.5% of participants achieving a minimum of a 3-point improvement in the MGC score and 63.6% versus 25.0% of participants achieving a minimum of a 3-point reduction in the MG-ADL score.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

> “The proportion of MGC score responders (≥5-point improvement) was significantly higher in the Descartes-08 AChR+ cohort vs placebo at Month 3: 63.6% vs 12.5% in placebo group (p=0.0258)”

Source: [Vu et al. (2026b)](https://www.cartesiantherapeutics.com/wp-content/uploads/260303_AChRP2B_Cartesian_MDA_oral-presentation_v4.0-Final.pdf)

<a id="topic-2.2.2.3-2"></a>

### Descartes-08: AChR antibody-positive subgroup, MG-ADL change at month 3 and through month 12 (phase 2b)

> “There was a significant and clinically meaningful reduction in the mean (s.d.) MG-ADL score at month 3 for the Descartes-08 group compared to the placebo group (−3.4 (2.84) versus 0.6 (2.93), P = 0.0409) (Extended Data Fig. 1).”
> “This reduction in the MG-ADL score was maintained up to month 12 for those in the Descartes-08 group.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

> “There was a significant and clinically meaningful reduction in mean [SD] MG-ADL score at Month 3 for the Descartes-08 AChR+ group versus placebo (-3.4 [2.8] vs -0.6 [2.9], p=0.0409)”

Source: [Vu et al. (2026b)](https://www.cartesiantherapeutics.com/wp-content/uploads/260303_AChRP2B_Cartesian_MDA_oral-presentation_v4.0-Final.pdf)

<a id="topic-2.2.2.3-3"></a>

### Descartes-08: AChR antibody status as a marker of response (phase 2b)

> “Similar trends in MGC response were observed between the overall cohort and the AChR autoantibody-positive population.”
> “Together, these results confirm that, while anti-AChR antibody status is useful in classifying disease, its relevance as a marker to track progression or response to treatment is limited”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

> “In line with this limitation, anti-AChR antibody titer did not correlate with change in clinical disease, as measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale (n = 21) (Fig. 3l and Extended Data Table 2).”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.2.2.3-4"></a>

### Descartes-08: biologic-naive versus biologic-exposed participants, post hoc analysis, mITT population (phase 2b)

> “A post hoc analysis was conducted to evaluate the magnitude of response to Descartes-08 in participants who were biologic-naive and those with prior biologic exposure.”
> “Participants with no prior exposure to complement inhibitors, FcRn inhibitors or CD19/CD20-targeting monoclonal antibodies (biologic-naive) demonstrated an improved response to Descartes-08 compared to those with prior biologic exposure, with 55.6% (n = 5/9) of participants achieving MSE by month 6, which was maintained through month 12.”
> “Additionally, the biologic-naive group had a greater proportion of MGC responders at month 3 compared to the group with prior biologic exposure (88.9% versus 33.3%).”
> “There were also notable reductions in MG severity scores from baseline to month 3 for the biologic-naive group versus those with prior biologic exposure (mean (s.d.) score: MGC −7.7 (5.24) versus 1.0 (6.96); MG-ADL −5.2 (3.27) versus −2.5 (3.08); QMG −5.0 (3.84) versus −2.2 (4.92)), with scores further improved by month 12 (MGC −11.0 (4.0), MG-ADL −7.1 (1.9), QMG −9.4 (2.6)) (Extended Data Table 5 and Extended Data Fig. 2).”
> “Notably, 100.0% of biologic-naive participants maintained at least a clinically meaningful response at month 12.”
> “Biologic-exposed participants were non-responders to prior FcRn or complement inhibitor treatment.”
> “Among biologic-naive patients, 55.60% achieved MSE by month 6, which was maintained through month 12 without additional treatment.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-5"></a>

### Descartes-08: authors' interpretation of the biologic-exposure difference (phase 2b)

> “There was a notable difference in response between participants who had prior treatment with—and poor response to—complement and FcRn inhibitors and those who were biologic-naive.”
> “This may represent a true difference in biology due to a yet-to-be-determined mechanism, an artifact of a small sample size or a reflection of more treatment-refractory disease.”
> “However, it is notable that, even in the cohort of patients who were nonresponders to biologics, a proportion achieved a clinically meaningful improvement in the MGC score after Descartes-08, in contrast to those who were randomized to placebo.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-6"></a>

### Descartes-08: biologic-naive participants with follow-up beyond month 3 (7 participants), company release, April 2025

> “The subset of participants who did not have exposure to prior biologic therapies, including complement or neonatal fragment crystallizable receptor (FcRn) inhibitors, were observed to exhibit a deepening of responses throughout the year, with an average MG-ADL reduction of 6.6 (±1.5) at Month 4 and 7.1 (±1.9) at Month 12.”
> “The participants treated with Descartes-08 without exposure to prior biologic therapies were observed to have an average QMG reduction of 5.9 (±2.4) points at Month 4, which deepened through Month 12 (9.4±2.6).”
> “57% (4/7) of these participants were observed to achieve MSE at Month 6 which was maintained through Month 12.”
> “100% (7/7) of these participants were observed to maintain at least a clinically meaningful response through Month 12.”

Source: [Cartesian Therapeutics phase 2b 12-month results press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-descartes-08-observed-provide-deep-and)

<a id="topic-2.2.2.3-7"></a>

### Descartes-08: early-onset versus late-onset disease, prespecified analysis, mITT population (phase 2b)

> “In a prespecified analysis stratifying participants by disease onset, 80.0% (n = 4/5) of those treated with Descartes-08 who had early-onset MG, defined as the development of symptoms before the age of 50 years, were MGC responders at month 3, compared to 20.0% (n = 1/5) in the placebo group (Extended Data Table 2).”
> “Reductions in MG severity were generally consistent between participants with early-onset MG and those with late-onset MG who were treated with Descartes-08.”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-8"></a>

### Descartes-08: triple seronegative participants and the placebo response (phase 2b)

> “The most pronounced improvements in MG severity scales in the placebo group—including one case of MSE—were observed in participants with triple seronegative MG, consistent with larger placebo-controlled studies that included this cohort of patients”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-9"></a>

### Descartes-08: postinfusion fever and response, mITT population (phase 2b)

> “There were no notable differences in demographics or disease characteristics among participants randomized to Descartes-08 who developed a fever.”
> “However, those who developed a fever may have been more likely to respond and experience more pronounced symptom improvement, as measured by the MG-ADL score, than those who did not (Extended Data Table 3).”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-10"></a>

### Descartes-08: cell dose and MGC response, post hoc analysis (phase 2b)

> “A second post hoc analysis was conducted to assess cell dose infusion and MGC response.”
> “Overall, the mean cell dose per infusion was similar among those treated with Descartes-08, irrespective of whether they achieved a response or not (Extended Data Table 6).”

Source: [Vu et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004676/)

<a id="topic-2.2.2.3-11"></a>

### Descartes-08: response across MG types and severity, phase 1b/2a long-term follow-up

> “The initial report of Descartes‐08 noted deep responses across MG types and degrees of severity [8].”

Source: [Chahin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12623823/)

<a id="topic-2.2.2.3-12"></a>

### MuSK antibody-positive disease: response to conventional therapies

> “Many patients with MuSK-MG respond poorly to ChEIs, and conventional pyridostigmine doses frequently induce side effects.”
> “Patients with MuSK-MG appear to respond well to corticosteroids and to many steroid-sparing IS agents. They tend to remain dependent on prednisone despite concomitant treatment with steroid-sparing agents.”
> “MuSK-MG responds well to PLEX, while IVIg seems to be less effective.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

<a id="topic-2.2.2.3-13"></a>

### MuSK antibody-positive disease: complement independence and thymectomy

> “The observation of predominant IgG4 antibodies in patients with MuSK MG is indicative of immune response that corresponds with the IgG4 autoimmune diseases ( 9 ) and the antiinflammatory properties of the IgG4 that include the inability to activate complement.”
> “The thymus is normal ( 116 ), and thymectomy does not benefit patients with MuSK with MG”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.3-14"></a>

### Rituximab response by antibody status

> “A retrospective combined analysis of previously published case reports of 169 patients between January 2000 and August 2015 reported that 72% of MuSK-Ab + MG and 30% of AChR-Ab+ MG patients treated with RTX achieved MM status or better.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-15"></a>

### Inebilizumab effect by antibody status

| Week 26 outcome | Overall population | Anti-AChR antibody positive | Anti-MuSK antibody positive |
| --- | --- | --- | --- |
| MG-ADL difference from placebo | “-1.9” | “-1.8” | “-2.2” |
| MG-ADL p-value | “<0.0001” | “0.0015” | “0.0297” |
| QMG difference from placebo | “-2.5” | “-2.5” | “-2.3” |
| QMG p-value | “0.0002” | “0.0011” | “NS” |

Source: [Uplizna prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761142s004lbl.pdf)

<a id="topic-2.2.2.3-16"></a>

### Seronegative disease: efgartigimod in anti-AChR antibody-negative adults

> “The efficacy of VYVGART for the treatment of adult patients with gMG who are anti-AChR antibody negative was established in an 8-week, randomized double-blind, placebo-controlled study (Study 2 Part A; NCT06298552).”
> “In Study 2 Part A, a total of 119 patients were randomized 1:1 to receive once-weekly infusions for 4 weeks of either VYVGART 10 mg/kg (1,200 mg for those weighing 120 kg or more) (n=58) or placebo (n=61).”
> “Sixty-one percent of patients were triple seronegative (i.e., anti-AChR, anti-MuSK, and anti-low- density lipoprotein receptor-related protein 4 [LRP4] antibodies negative). Thirty-four percent of patients were positive for anti-MuSK antibodies, and 5% of patients were positive for anti-LRP4 antibodies.”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.3-17"></a>

### Antibody subgroups enrolled in FcRn blocker trials

> “The majority of patients, 89.5% (n=179) were positive for AChR antibodies and 10.5% (n=21) were positive for MuSK antibodies.”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

> “Eighty-eight percent (n=134) of patients were positive for AChR antibodies and 10% (n=16) were positive for MuSK antibodies.”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.2.2.3-18"></a>

### Ocular versus generalized disease

> “The efficacy of IVIg is less certain in milder MG or in ocular MG.”

Source: [Sanders et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4977114/)

> “Corticosteroids should be used as the initial IS agent in ocular MG. Steroid-sparing IS agents may be needed when corticosteroids alone are ineffective, contraindicated, or not tolerated”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-19"></a>

### Age and thymectomy benefit

> “In a post hoc analysis, neither the prednisone dose nor QMG scores were significantly different between the 2 treatment groups in patients 50 years or older.”

Source: [Narayanaswami et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884987/)

<a id="topic-2.2.2.3-20"></a>

### Potential confounding of network meta-analysis treatment effects by age and sex

> “Sensitivity analyses detected potential confounding of treatment effects by age and sex.”
> “Our findings also highlight how differences between trial populations may confound the interpretation of study outcomes.”

Source: [McLaren et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42467874/)

<a id="topic-2.2.2.3-21"></a>

### Delayed response to C5 inhibition in therapy-refractory patients: German-Austrian expert guidance

> “A clinical response is generally observed within the first 4 weeks after treatment initiation. In patients who do not achieve clinically meaningful improvement within 12 weeks, the decision to continue treatment or switch to an alternative therapy should be individualised [15, 17, 18, 20], as long‐term observational data from non‐placebo‐controlled studies suggest that delayed responses may occur, particularly in therapy‐refractory gMG patients treated with eculizumab or ravulizumab for several months or longer [39, 40].”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
